NCT06528249View on ClinicalTrials.gov

Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
CancerSolid TumorHematologic Malignancy
Interventions
DRUG

Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes

Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes

All Listed Sponsors
collaborator

Westlake Therapeutics

INDUSTRY

lead

Zhejiang Provincial People's Hospital

OTHER

NCT06528249 - Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies | Biotech Hunter | Biotech Hunter